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Background: Smad4 functions as a common mediator of transforming growth
factor β (TGF-β) signaling by forming complexes with the phosphorylated state
of pathway-restricted SMAD proteins that act in specific signaling pathways to
activate transcription. SMAD proteins comprise two domains, the MH1 and
MH2 domain, separated by a linker region. The transcriptional activity and
synergistic effect of Smad4 require a stretch of proline-rich sequence, the
SMAD-activation domain (SAD), located N-terminal of the MH2 domain. To
understand how the SAD contributes to Smad4 function, the crystal structure
of a fragment including the SAD and MH2 domain (S4AF) was determined.
Results: The structure of the S4AF trimer reveals novel features important for
Smad4 function. A Smad4-specific sequence insertion within the MH2 domain
interacts with the C-terminal tail to form a structural extension from the core.
This extension (the TOWER) contains a solvent-accessible glutamine-rich helix.
The SAD reinforces the TOWER and the structural core through interactions;
two residues involved in these interactions are targets of tumorigenic mutation.
The solvent-accessible proline residues of the SAD are located on the same
face as the glutamine-rich helix of the TOWER, forming a potential transcription
activation surface. A tandem sulfate-ion-binding site was identified within the
subunit interface, which may interact with the phosphorylated C-terminal
sequence of pathway-restricted SMAD proteins.
Conclusions: The structure suggests that the SAD provides transcriptional
capability by reinforcing the structural core and coordinating with the TOWER
to present the proline-rich and glutamine-rich surfaces for interaction with
transcription partners. The sulfate-ion-binding sites are potential ‘receptors’ for
the phosphorylated sequence of pathway-restricted SMAD proteins in forming a
heteromeric complex. The structure thus provides a new model that can be
tested using biochemical and cellular approaches.
Introduction
Members of the transforming growth factor-β (TGF-β)
family of cytokines, such as TGF-βs, activins and bone
morphogenetic proteins (BMPs), have important roles in
early embryonic patterning and physiological regulation in
vertebrates and invertebrates [1–3]. Cloning and charac-
terization of the receptors for the TGF-β family of ligands
reveals that these cytokines signal through two types of
interacting transmembrane serine/threonine kinase recep-
tors [4]. Ligand binding induces and stabilizes association
between type I and type II receptors, which triggers phos-
phorylation and activation of the intracellular kinase
domain of the type I receptor by the constitutive intra-
cellular kinase domain of the type II receptor [5]. 
After receptor kinase activation, the signals of the TGF-β
family of ligands are regulated by a set of evolutionarily
conserved proteins known as SMAD proteins. Eight
SMAD proteins have been characterized in vertebrates
[6–8]. The current model suggests that Smad4, also
known as DPC4 (deleted in pancreatic carcinoma
locus 4), has a central role in signal distribution by associ-
ating as hetero-oligomers with pathway-restricted SMAD
proteins, Smad1, 2, 3, 5 and 8 [9–11]. Unlike Smad4,
pathway-restricted SMAD proteins function in specific
signaling pathways. Smad1, 5 and 8 mediate the signals
of BMPs, whereas Smad2 and Smad3 mediate the signals
of activins and TGF-βs [10,12–14]. Upon ligand stimula-
tion, pathway-restricted SMAD proteins are phosphory-
lated at the conserved C-terminal tail sequence, SS*XS*
(where * denotes a site of phosphorylation), by the type I
receptor kinase [15,16]. The phosphorylated states of
pathway-restricted SMAD proteins form heteromeric
complexes with Smad4 and are translocated into the
nucleus. In the nucleus, the heteromeric complexes func-
tion as gene-specific transcription activators by binding to
promoters and interacting with transcriptional coactiva-
tors. Smad6 and Smad7 are inhibitory SMAD proteins
that inhibit TGF-β signaling by interfering with either
receptor-mediated phosphorylation or hetero-oligomer-
ization between Smad4 and pathway-restricted SMAD
proteins [17–20].
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SMAD proteins share a common domain configuration con-
sisting of the highly conserved N-terminal domain (MH1
domain) and C-terminal domain (MH2 domain) separated
by a variable proline-rich linker region (L domain). For
pathway-restricted SMAD proteins and Smad4, the MH2
domain has a role in transcription activation [11,14,21],
whereas the MH1 domain has a role in DNA binding
[22,23]. The transcription activity of the Smad4 MH2
domain requires a stretch of proline-rich sequence from the
L domain. When fused to a heterologous GAL4 DNA-
binding domain, Smad4(266–552) displays constitutive
transcription activity whereas Smad4(322–552) is inactive
[9,14,24]. Further mapping of the region defined residues
274–322 as the Smad4 activation domain (SAD), which is
indispensable for transcription activation and signaling syn-
ergism [11,24]. Nevertheless, the structural basis as to how
SAD contributes to transcription activation and signaling
synergism remains unknown. 
The TGF-β family of ligands induce growth arrest by reg-
ulating the expression level of cell-cycle components
[25,26]. Mutations that lead to loss of TGF-β signaling
function are often associated with cancers [27]. Smad4 is
mutated in a significant proportion of pancreatic [28] and
colorectal tumors [29,30] and less frequently in breast [31],
ovarian [31], head and neck [32], prostatic [30], esophageal
and gastric cancers [33]. Mutations of Smad2 have also
been found to be associated with colon cancers [34]. The
tumorigenic mutations are clustered within the MH2
domain, which is consistent with the effector function of
this domain in signaling.
The crystal structure of the Smad4 MH2 domain (residues
319–552) suggests that the functional unit of SMAD pro-
teins is trimeric. The MH2 domain forms a crystallo-
graphic trimer through a conserved protein–protein
interface to which the majority of the tumor-derived mis-
sense mutations map [35]. Other tumor-derived missense
mutations map to the highly conserved L3 loop (residues
506–522). Mutation of the L3 loop disrupts heteromeric
interaction between Smad4 and pathway-restricted
SMAD proteins, leading to the proposal that the hetero-
meric complex is a hexamer composed of two trimers
interacting via the L3 loops.
In this report, the crystal structure of the transcriptionally
active Smad4 fragment (S4AF), including the SAD and
MH2 domains (residues 273–522), is described. The
S4AF forms a trimer in the asymmetric unit, which packs
in a similar manner to the crystallographic trimer of the
MH2 domain. A model of transcription activation is pre-
sented on the basis of the SAD structure. The identifica-
tion of sulfate-ion-binding sites also yields insight into the
molecular basis of phosphorylation-induced heteromeric
interaction between Smad4 and pathway-restricted
SMAD proteins. 
Results and discussion
The active Smad4 fragment forms an asymmetric trimer
The three-dimensional structure of the functionally active
Smad4 fragment (S4AF; residues 273–552) was deter-
mined by molecular replacement using the Smad4 MH2
domain (319–543) coordinates as a search model (Table 1).
The asymmetric unit contains three S4AF molecules,
which pack in a similar manner to the proposed functional
trimer of the Smad4 MH2 domain [35]. The final model of
the S4AF trimer includes three non-equivalent subunits,
ten sulfate ions, and 321 water molecules. The R and Rfree
factors are 17.4% and 21.8%, respectively, for all data from
100–2.6 Å. The statistics for the overall stereochemistry of
the S4AF model are excellent with root mean square devi-
ations (rmsds) from standard geometry of 0.0058 Å for
bond lengths and 1.207° for bond angles.
The three S4AF subunits exhibit different degrees of dis-
order: subunit A contains residues 285–296, 311–460 and
487–545; subunit B contains residues 285–296, 307–469 and
479–552; subunit C contains residues 285–294, 312–468
and 479–552. Subunit B resembles subunit C in that addi-
tional electron density is visible for residues 458–469,
479–490 and the C-terminal tail residues 545–552. These
regions interact to form a structural extension from the
core, which is referred to as the TOWER (Figure 1). The
corresponding regions are disordered in the previous struc-
ture of the Smad4 MH2 domain and partially disordered in
subunit A. Consistent with subunit B and C having more
closely related structures, the rmsd for Cα atoms (residues
319–456 and 490–543) between subunits B and C is slightly
smaller (0.24 Å) than that between subunits A and B
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Table 1
Summary of crystal parameters, crystallographic data and
refinement statistics.
Crystal parameters and crystallographic data
Space group I4(1)22
Unit-cell dimensions (Å) a = 142.43, c = 195.48
Diffraction limits (Å) 100–2.62 (2.68–2.62)
Total reflections 149,962
Unique reflections 29,751
Completeness (%) 98.2 (96.3)
I/σ 11.19 (2.01)
Rmerge (%)* 14.3 (76.5)
Refinement statistics
Number of protein atoms 5543
Number of water molecules 317
Number of sulfate ions 10
R factor (%)† 17.44
Rfree (%)‡ 21.80
Rmsd from ideal
bond lengths (Å) 0.0058
bond angles (°) 1.207
Values in brackets are for the highest resolution shell.
*Rmerge = Σ |Ihkl – <Ihkl>|/Σ Ihkl. †R factor = Σhkl ||Fobs| — |Fcalc||/Σhkl |Fobs|
for all data. ‡Rfree = Σhkl ||Fobs| – |Fcalc||/Σhkl |Fobs| for 10% of the data not
used in refinement.
(0.29 Å) or between subunits A and C (0.30 Å). The rmsd
values for Cα atoms between the Smad4 MH2 domain
structure and each of the three S4AF subunits are 0.34, 0.32
and 0.36 Å, suggesting that there are no major structural
differences over the superimposable region.
Instead of forming a structural domain, the functionally
defined Smad4-activation domain (SAD) [24], residues
274–322, forms part of the core structure (Figure 1). The
SAD extends from the N terminus of the previous Smad4
MH2 domain structure as a loop (SAD loop), passes
around the base of the TOWER, and forms a parallel 
β strand (SAD-β) against strand β8. The presence of the
SAD results in the extension of the twisted β-sheet A from
six to seven strands (Figure 1b).
The locations of the ten sulfate ions are shown in Figure 1a.
There are three sulfate-binding sites in each subunit. Sites
1 and 2 are located near the base of the TOWER, whereas
site 3 is located near the L3 loop. They are referred to as
sites Sa1, Sa2, Sa3, Sb1, Sb2, Sb3, Sc1, Sc2 and Sc3, on the
basis of the sites and their subunit association. The tenth
sulfate-binding site is located in-between subunits B and C
near site Sc2, and is referred to as site Sbc.
The SAD presents a proline-rich hydrophobic surface
The SAD sequence is highly proline-rich (27%). In the
crystal structure of S4AF, the SAD forms two well-ordered
structures (residues 285–296 and 307–318) separated by a
disordered region (residues 297–306; Figure 2). Residues
288–291 form a parallel β strand (SAD-β) along β8, and
extend the twisted β sheet A (Figure 1b). Residues 307–318
form an extended loop structure (SAD loop) encompassing
the base of the TOWER and connect to the MH2 domain.
There are extensive interactions between the SAD and the
MH2 domain, which contribute to stabilization of the core
structure and the TOWER. In addition to the β-strand
interactions between SAD-β and β8, residues towards the
N-terminal end of SAD-β (residues 286–289) interact with
the L3 loop and the loop N-terminal of β8, referred to as
the L420 loop (Figure 2, right-hand inset). One prominent
set of hydrogen-bonding interactions occurs between the
guanidinyl group of Arg420 within the L420 loop and the
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Figure 1
The overall structure of S4AF. (a) The S4AF trimer in the asymmetric
unit. Additional structural features in comparison to the previous MH2
domain model are shown in purple (subunit A), green (subunit B) and
red (subunit C). Disordered regions are represented by dotted lines.
The core of each subunit is composed of two twisted β sheets packing
against each other. The TOWER, containing three helices and two
β strands, forms a structural extension from the core. The SAD
encompasses the base of the TOWER (behind the TOWER in this
view) and forms a β strand along the core, extending β sheet A (top
sheet in this view) from six to seven strands. Sulfate molecules are
shown in ball-and-stick representation, and are colored according to
their subunit association. The sulfate ion in site Sbc is colored yellow.
(The programs MOLSCRIPT and RASTER3D were used in the
preparation of this figure [52,53].) (b) Topology diagram of S4AF
subunit B. Additional structural features in comparison to the MH2
domain model are colored in green. The disordered regions (residues
273–284, 297–306 and 470–478) are represented by dotted lines.
The β sheets A and B of the structural core are distinguished by a gray
scale (sheet A, medium gray; sheet B, dark gray). 
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backbone of residues 286 and 287 of SAD. Arg420 is a
target of tumorigenic mutation in Smad4. The interaction
between Arg420 and the SAD stabilizes SAD-β as part of
an extended structural core. Moreover, the His287
sidechain of SAD-β wedges into the space between the
L420 and L3 loops and interacts through van der Waals
contacts. The extended structural core is further stabilized
by hydrophobic interactions mediated by Leu288 of
SAD-β, Tyr513 of the L3 loop and Phe408 of β7. Residues
C-terminal to SAD-β contain a stretch of solvent-exposed
hydrophobic residues, PPMPP (single-letter amino acid
notation). This region makes no interaction with the core
and leads to a disordered region (residues 298–306) which
is also hydrophobic in content (PGHYWPVHN). 
The SAD loop interacts with the base of the TOWER and
the loop connecting β5 and β6 (referred to as the L390
loop) through hydrogen-bonding and hydrophobic inter-
actions (Figure 2, left-hand inset). Most of the hydrogen-
bonding interactions are mediated between the TOWER
sidechains and the SAD loop backbone. One of the hydro-
gen-bonding interactions is between the Arg441 sidechain
and the Pro312 carbonyl oxygen. Arg441 is also a target of
tumorigenic mutation in Smad4. The structure provides a
basis for mutation-induced tumorigenicity and under-
scores the role of SAD in Smad4 function. The interaction
between the SAD loop and the TOWER is further stabi-
lized through a hydrophobic center formed by Ile314 of
the SAD loop and Leu535 and Leu440 of the TOWER.
Most of the hydrophobic residues of the SAD loop are
solvent-exposed. These residues include Phe310, Pro312,
Pro313 and Pro318. The SAD thus presents an unusually
proline-rich, hydrophobic surface which may mediate
interaction with other proteins to activate transcription.
Proline-rich sequences in transcription factors have been
demonstrated to activate transcription. CTF (CCAAT box
transcription factor)/NFI (nuclear factor I) and AP-2 (acti-
vator protein 2) are examples of a growing list of transcrip-
tion factors that contain proline-rich activation domains
[36–39]. How proline-rich sequences activate transcription
is not understood, but the general view is that they are
probably involved in docking with other transcription
factors. The proline-rich SAD has been found to have an
essential role in transcription activation and signaling syn-
ergism [11,24]. The structure of S4AF shows that these
proline residues, together with the adjacent hydrophobic
residues, are exposed on the surface of the protein. This
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The SAD presents a proline-rich hydrophobic surface. The SAD is
shown in green; disordered regions are represented by dotted lines.
The inset on the left shows detailed interactions between the SAD
loop and the base of the TOWER. Pro312 of the SAD loop has a
mainchain hydrogen-bond interaction with the sidechain of Arg441,
which is a target of tumorigenic mutation. The inset on the right shows
the detailed interactions of SAD-β. Both Gly286 and His287 form
mainchain hydrogen-bond interactions with the sidechain of Arg420,
which is also a target of tumorigenic mutation. At the C-terminal end of
SAD-β, a proline-rich segment (PPMPP) extends towards the
disordered hydrophobic region of SAD. (The programs MOLSCRIPT
and RASTER3D were used in the preparation of this figure [52,53].)
energetically unfavorable surface could be stabilized
through hydrophobic interaction with a transcription
partner. The transcription activation function of Smad4
SAD has recently been shown to depend on the coactiva-
tor p300, and to involve physical interaction between the
SAD and the N terminus of p300 [40].
The corresponding SAD sequences in nonmammalian
Smad4 isoforms are not highly conserved (Figure 3). Never-
theless, the proline-rich pattern remains characteristic of this
region (15% proline in Drosophila, 14% in Caenorhabditis
elegans). The sequence variation may reflect structural differ-
ences of the interacting partners for transcription activation.
The TOWER is poised for interaction
A distinct structural feature in subunits B and C of the S4AF
trimer is the elongated cylindrical extension, the TOWER,
which is ~50 Å in length and 20 Å in diameter and extends
from the core. The axis of the extension is approximately
perpendicular to the core β sheets. The TOWER is formed
by two separate segments of the primary sequence, residues
440–500 and 531–552 (Figure 4). The segment from
residues 440–500 extends from the core as a long helix (H3)
to the top of the TOWER, returns forming a β strand (βt1)
to half-height, and becomes a helix (H4) returning to the
core. The C-terminal segment from residues 531 to the
C terminus protrudes from the core as a helix (H5) and
transforms into a β strand (βt2) extending to the top of the
TOWER. The TOWER structure is stabilized through
hydrophobic sidechain interactions of the three-helix
bundle (H3, H4 and H5) at the base, as well as antiparallel
β-sheet (βt1 and βt2) packing against the long helix (H3) at
the distal end. At the top of the TOWER, residues 470–478,
which connect the long helix and the returning β strand, are
not observable as a result of disordering. In the crystal struc-
ture of the Smad4 MH2 domain, only the base of the
TOWER was observed as a result of disordering of residues
457–491 and 544–552 [35].
The TOWER is a conserved feature in Smad4 and is
absent in pathway-restricted SMAD proteins. Sequence
alignment of SMAD proteins reveals that all Smad4 iso-
forms contain a unique insert of about 35 residues within
the MH2 domain (Figure 3). This insert corresponds to
residues 443–477 of human Smad4, which form the long
helix (H3) extending from the base to the top of the
TOWER. The insert contains sequence rich in glutamine
and alanine residues. The glutamine-rich sequences belong
to a class of activation domains known from transcription
factors such as Sp1, Oct-1 and Oct-2 [37,41,42]. Although
the structural basis of action for this class of transactivation
domains is poorly understood, they are in general thought
to mediate specific protein–protein contacts with other
transcription partners. In the crystal structure of the human
papillomavirus type 18 E2 activation domain, the N-termi-
nal glutamine-rich activation sequence forms an amphi-
pathic helix with the glutamine sidechains exposed to the
solvent [43]. A similar disposition of the glutamine residues
within the long helix of the TOWER suggests that they
may have a similar role in transcription activation. The
invariable AQAAAVAG motif (residues 460–467) within
the insert of Smad4 isoforms is located at the distal end of
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Figure 3
Sequence alignments of the SAD, TOWER
and C-terminal tail regions of SMAD proteins.
Smad4 isoforms from human, rat, mouse,
Xenopus (XENO), medea (MEDEA) and C.
elegans (CELEG) are underlined. The
conserved residues of Smad4 sequences are
shown in red; the invariable residues in all
SMAD proteins are in green. The Smad1,
Smad2, Smad3, Smad5, Smad6 and Smad 7
sequences are from human. The Smad8
sequence is from rat. Secondary structures are
indicated by # (helix), ~ (loop), and ⇒ (strand).
HUMAN  IKVFDLRQCHRQMQQQAATAQAAAAAQAAAVAGNIPGPGSVGGIAPAISLSAAAGI-GVDDLRRL CILRMSFVK
RAT    IKVFDLRQCHRQMQQQAATAQAAAAAQAAAVAGNIPGPGSVGGIAPAISLSAAAGI-GVDDLRRL CILRMSFVK
MOUSE  IKVFDLRQCHRQMQQQAATAQAAAAAQAAAVAGNIPGPGSVGGIAPAISLSAAAGI-GVDDLRRL CILRMSFVK
XENOα  IKVFDLRQCHRQMQQQAATAQAAAAAQAAAVAGNIPGPGSVGGIAPAISLSAAAGI-GVDDLRRL CILRMSFVK
XENOβ  IKVFDLRQCHRQMQQQAATAQAAAAAQAAAVAGAIPGPGSVGGIAPAVSLSAAAGI-GVDDLRRL CILRLSFVK
MEDEA  IKVFDLRQCHQQMHSLATNAQAAAAAQAAAVAGVANQQMGGGGRSMT AAAGI-GVDDLRRL CILRLSFVK
CELEG  FTVFDIRWAYMQMLRRSRSSNEAVRAQAAAVAGYAPMSVMP AIMPDSGVDRMRRDFCTIAISFVK
SMAD1  LKIFNNQEFAQLLAQSVNHGFETVY ELTKMCTIRMSFVK
SMAD2  LKIFNNQEFAALLAQSVNQGFEAVY QLTRMCTIRMSFVK
SMAD3  LKIFNNQEFAALLAQSVNQGFEAVY QLTRMCTIRMSFVK
SMAD5  LKIFNNQEFAQLLAQSVNHGFEAVY ELTKMCTIRMSFVK
SMAD8  LKVFNNQLFAQLLAQLLAQSVHHGFEVVY ELTKMCTIRMSFVK
SMAD6  IKVFDFERSGLQHAPEPDAAD GPYDPNSVRISFAK
SMAD7  IKAFDYEKAYSLQRPNDHEFMQ QPWTGFTVQISFVK
       ====>###########################~~~          ~~=====>~~~~~######=== ===>~~ 
552150 507435MH1 MH2Linker1 273
S4AF
Smad4/DPC4 HUMAN
543
HUMAN  APYTPNLPHHQNGHLQHHPPMPPH PGHYWPVHNELAFQPPIS NHPAPEY WCSI     EIHLHRALQLLDEVLHTMPIADPQPLD--
RAT    APYTPNLPHHQNGHLQHHPPMPPH PGHYWPVHNELAFQPPIS NHPAPEY WCSI     EIHLHRALQLLDEVLHTMPIADPQPLD--
MOUSE  APYTPNLPHHQNGHLQHHPRMPPH PGHYWPVHNELAFQPPIS NHPAPEY WCSI     EIHLHRALQLLDEVLHTMPIADPQPLD--
XENOa  AAYTPNMSHHPNGHLQHHPPMPH PGHYWPVHNELAFQPPIS NHPAPDY WCSI     EIHLHRALQLLDEVLHTMPIADPQPLD--
XENOb  AVYTPNPGVQQNGRGNQQPPLHH PNNYWPLHQSSPQYQHPVS NHPGPEF WCSV     EVHLHRALQLLDEVLHTLPMADPSSVN--
MEDEA  SMQPPDPRSLPGGFWNSSLSGDLGS PQQTPPQQQQQQQQPRLLS RQPPPEY WCSI     EVHLHRALQLLDEVLHAMPIDGPRAAA--
CELEG  AGVIDSCSDWPNTPPDNNFNGGFAPDQ PQLVTPIISDIPIDLNQIYVPTPPQLLDNWCSI     EVTLHRPLQILDQLLKNSSQFGSS-----
SMAD1  PPPAYLPPEDPMTQDGSQPMDTNMMAPPLPSEINRGDVQAVAY EEPKH WCSI     EIHLHGPLQWLDKVLTQMGSPHNPISSVS
SMAD2  PPPGYISEDGETSDQQLNQSMDTGSPAELSPTTLSPVNHSLDLQPVTY SEPAF WCSI     ELHLNGPLQWLDKVLTQMGSPSVRCSSMS
SMAD3  PPPGYLSEDGETSDHQMNHSMDAGSPNLSPNPMSPAHNNLDLQPVTY CEPAF WCSI     ELHLNGPLQWLDKVLTQMGSPSIRCSSVS
SMAD5  PPPAYMPPDDQMGQDPSQPMDTSNNMIPQIMPSISSRDVQPVAY EEPKH WCSI     EIHLHGPLQWLDKVLTQMGSPLNPISSVS
SMAD8  APPSSPGHVFPQSPCPTSYPQSPGSPSESDSPYQHSDFRPVCY EEPLH WCSV     EIHLHGPLQWLDKVLTQMGSPHNPISSVS
SMAD6  SRLSPRDEYKPLDLSDSTLSYTETEATNSLITAPGEFSDASM SPDATKPSHWCSV     EILLNNPR---------------------
SMAD7  SRYPMDFLKPTADCPDAVPSSAETGGTNYLAPGGLSDSQLLL EPGDRSH WCVV     EVIFNSR----------------------
                  ~~====>~~~~~                  ~~~~~~~~~~~~~~======     ===>#############~~~ ~~==>~~
TOWER
SAD C-terminal tail
322
Structure
the long helix immediately before the disordered region.
The sidechain of Val465 is solvent-exposed, which may
mediate interaction with other proteins. The use of a helix
to interact with target transcription factors has been
reported for the activation domains of p53 [44], CREB
(cyclic AMP responsive element binding protein) [45] and
VP16 (herpes simplex virus protein 16) [46]. In these cases,
the activation segments were disordered in the unbound
state and were induced to form amphipathic helices upon
binding their transcription partners. 
The glutamine-rich helix of the TOWER is on the same
face as the proline-rich hydrophobic sequence of SAD,
forming a potential surface for transcription activation
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The TOWER region of Smad4. (a) The TOWER region (red). Glutamine sidechains are shown in blue, hydrophobic core residues are in yellow.
Hydrogen-bond interactions between the TOWER and the neighboring subunit (green) are shown. (b) Image looking down the TOWER axis,
related to (a) by a 90° rotation about the x axis. (The programs MOLSCRIPT and RASTER3D were used in the preparation of this figure [52,53].)
Figure 5
A potential surface for transcription activation.
(a) The glutamine-rich region of the TOWER
is located on the same face of the subunit as
the proline-rich sequence of the SAD.
Glutamine residues are in purple and proline
residues in green. The AQAAAVAG motif (in
red) is located at the distal end of the long
helix of the TOWER region. (b) The potential
transcription activation surface is located at
the edge of the S4AF trimer. (The programs
MOLSCRIPT and RASTER3D were used in
the preparation of this figure [52,53].)
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(Figure 5). In the context of the S4AF functional trimer,
this putative transcription activation surface is located at
the periphery of the trimeric disk. This surface is likely to
be greatly altered in pathway-restricted SMAD proteins,
as they do not possess the Smad4-specific insert within
the TOWER. This unique surface in Smad4 may be able
to recruit a specific transcription activator and contributes
to the ability of Smad4 to synergize with pathway-
restricted SMAD proteins in signaling.
The antiparallel β-strand interaction in the TOWER,
which ties up the C-terminal tail of Smad4, is unlikely to
form in pathway-restricted SMAD proteins because of
their reduced TOWER structure. This architectural alter-
ation allows the conserved C-terminal phosphorylation
sites of the pathway-restricted SMAD proteins to be freely
accessible to kinases.
The TOWER also contributes to a significant portion of
the trimer interface (Figure 5). The helices H4 and H5 of
the TOWER are involved in hydrogen-bonding and
hydrophobic interactions with helix H1 and loops L1, L2
of the neighboring subunit. The buried surface area of the
S4AF trimer is larger than that of the MH2 domain trimer
(5800 Å2 verus 4800 Å2) as a result of the ordering of the
TOWER structure.
The sulfate-binding site as potential phosphorylation switch
Ten electron-density peaks consistent with bound sulfate
ions from the crystallization medium were identified in the
Fo–Fc map of the S4AF trimer (Figure 6). These peaks are
above 5σ in intensity, spherical in shape, and surrounded
by basic residues. Sites 1, 2 and 3 are present in all three
subunits at the same corresponding positions (Sa1, Sa2,
Sa3, Sb1, Sb2, Sb3, Sc1, Sc2 and Sc3). Site Sbc is present
between subunits B and C adjacent to site Sc2, and is the
only site where the sulfate ion is coordinated by residues
from two subunits. The current model suggests that phos-
phorylation of pathway-restricted SMAD proteins at the
C-terminal consensus sequence, SS*XS*, drives het-
eromeric interaction with Smad4 via the C-terminal
domain. A recent report showed that Smad4 binds specifi-
cally to the phosphorylated form of Smad2 C-terminal
peptide, suggesting that the phosphorylated tail of
pathway-restricted SMAD proteins bridges the hetero-
meric interaction [16]. As the chemistry and mode of
binding of a sulfate ion is similar to that of a phosphate ion,
the sulfate-binding sites identified in the S4AF trimer
might correspond to the sites of interaction of the phospho-
rylated C-terminal tail. To fulfill the function of a receptor
site for the phosphorylated C-terminal tail ‘ligand’, the site
should be conserved among Smad4 isoforms because of the
conservation of the interacting phosphorylation sequence. 
Sulfate-binding site 1 is located at the base of the
TOWER away from the trimer interface. The sulfate ion
is coordinated by the sidechains of Arg445 and Gln442
from the TOWER helix H3, and Arg416 from helix H2
(Figure 7a). This site is less likely to interact with the
phosphorylated C-terminal tail because all three residues
involved in sulfate binding are not conserved. Further-
more, the sulfate ion is simultaneously coordinated by
the same set of residues from the symmetry-related sub-
units, suggesting that it has a role in crystal packing. The
sulfate ion in site 2 is located at the base of the TOWER
near the trimer interface. The sulfate ion is coordinated
by the sidechains of Arg497 from helix H4 and Arg502
from strand β10 (Figure 7b). Arg497 and Arg502 are well
conserved among Smad4 isoforms, with the exception
that in C. elegans, the corresponding residue of Arg502 is
an alanine. Sulfate-binding site 3 is located within the L3
loop. The sulfate ion is coordinated by the sidechains of
Lys507 and Arg515, which are conserved in all SMAD
proteins (Figure 7c). Sulfate-binding site Sbc is located
in-between subunits B and C. The sulfate ion is coordi-
nated by the sidechains of Arg496 and Arg497 from
subunit C, and the sidechain of Arg372 and the backbone
of Asn369 from subunit B (Figure 7d). These interactions
are conserved among all Smad4 isoforms. Site Sbc is adja-
cent to site Sc2, forming a unique tandem sulfate-binding
site. The two sulfate ions are 3.9 Å apart (sulfur to sulfur)
and interact through hydrogen-bond interactions. The
sites corresponding to Sbc in the other two interfaces do
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Figure 6
The electron density of sulfate ions (Sa1, Sa2 etc.) as shown by the
Fo–Fc map. The map was calculated after simulated annealing refinement
without including the coordinates of the sulfate ions. The map is
contoured at the 5σ level. The S4AF trimer is shown as a Cα trace.
Subunits A, B and C are colored in blue, green and red, respectively.
B
A
C
Sb1
Sa1
Sc1
Sb2
Sa2
Sc2Sb3
Sa3
Sc3
Sbc
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not bind sulfate ions. Examination of the structure
reveals that this is due to the asymmetric packing of the
trimer in which the subunit interface between subunits B
and C is uniquely juxtaposed to bind an additional
sulfate ion (Figure 8).
The analysis reveals two highly conserved locations on
Smad4 that are candidate ‘receptors’ for the phosphory-
lated C-terminal tail of pathway-restricted SMAD pro-
teins. One is site 3 within the L3 loop, and the other
comprises the tandem sulfate sites between subunits B
and C (sites Sc2 and Sbc). It is interesting that the tandem
arrangement of the sulfate ions in sites Sbc and Sc2 is
reminiscent of the arrangement of the phosphoryl groups
in the doubly phosphorylated C-terminal sequence. This
unique location of the tandem sulfate ions in between
subunits B and C is opposite to subunit A, which has a dis-
ordered TOWER structure mimicking the subunit of a
pathway-restricted SMAD protein. Biochemical studies
using lysates from cells transfected with SMAD expres-
sion plasmids suggested that the association between
Smad4 and pathway-restricted SMAD protein may be het-
erotrimeric [47]. The oligomerization of SMAD proteins
was studied in the basal state when no receptor kinase was
cotransfected, or in the activated state when a constitutive
type I receptor kinase was cotransfected. In this case,
SMAD proteins exist mainly as monomers in the basal
state and undergo homo- and hetero-oligomerization after
activation. On a size-exclusion column, the Smad2–Smad4
heterocomplex elutes with smaller apparent molecular
weight than the Smad2 homo-oligomer, which is inconsis-
tent with the hexamer model. The S4AF trimer in the
asymmetric unit may suggest how heterotrimeric inter-
actions occur. A 2:1 complex composed of two Smad4 sub-
units (subunits B and C) and one pathway-restricted
SMAD protein subunit (subunit A) can form upon phos-
phorylation. The phosphorylated C-terminal tail of the
pathway-restricted SMAD subunit extends to the inter-
face between two Smad4 subunits to tighten the inter-
action (Figure 9). This model requires the phosphorylated
C-terminal ten residues to be in the extended conforma-
tion. The model suggests that phosphorylation will
tighten the trimeric interactions, which is in agreement
with the observation that SMAD proteins exist as
monomers in solution, and oligomerize upon receptor-
mediated phosphorylation [47].
An alternative model proposes site 3 within the L3 loop of
Smad4 as the ‘receptor’ for the phosphorylated C-terminal
tail. Although this site contains only a single sulfate ion in
all three subunits, there are additional highly conserved
basic residues nearby (Arg378 and Lys428) which could
potentially interact with the doubly phosphorylated C-ter-
minal sequence. Utilization of the L3 loop in heteromeric
interactions has been proposed to occur through the flat
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Figure 7
Sulfate-ion-binding site constellation. (a) Sulfate-binding site 1.
(b) Sulfate-binding site 2. (c) Sulfate-binding site 3. (d) Sulfate-binding
site bc. Subunits B and C are colored in green and red, respectively.
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Figure 8
Subunit-to-subunit juxtaposition around the
tandem sulfate ions are compared by a
stereoview superimposition of subunit pairs
B–C (red), A–B (green), C–A (blue) and two
subunits of the symmetry-related MH2 domain
trimer (yellow). Superimposition was performed
on the Cα atoms of residues 493–502 of one
subunit. The average displacements of the Cα
atoms (residues 364–380) in comparison to
the B–C pair are 1.16 Å (A–B pair), 0.57 Å
(C–A pair) and 0.93 Å (MH2 domain pair). The
maximum displacements are 1.88 Å (Cα 374),
0.94 Å (Cα 373) and 1.28 Å (Cα 374) for
subunit pairs A–B, C–A and the MH2
domain, respectively.
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surface of two trimers, which results in a hexamer [22].
Further investigations will be required to discriminate
between these models.
Biological implications
The transforming growth factor β (TGF-β) family of
cytokines regulate cellular processes of diverse organ-
isms by switching on a class of transcription factors
named SMAD proteins. Following ligand-induced recep-
tor kinase activation, the phosphorylated forms of
pathway-restricted SMAD proteins form active com-
plexes with Smad4, which shuttle into the nucleus to
turn on specific genes.
The first functionally active Smad4 structure (S4AF) is
presented here. S4AF contains the C-terminal domain
of Smad4 (the MH2 domain) together with a proline-
rich region (the SMAD-activation domain; SAD) which
is indispensable for Smad4 signaling and transcription
functions. The SAD structure encompasses the peri-
phery of the functional S4AF trimer, exposing its
proline-rich hydrophobic residues to the solvent. This
unfavorable display of hydrophobic surface is stabilized
by the flanking sequences that interact with the struc-
tural core. The structure therefore suggests a general
means by which proline-rich transactivation sequences
can be disposed on transcription factors for interaction
with coactivators. The SAD is located on the same face
as a solvent-accessible glutamine-rich helix of the MH2
domain. Glutamine-rich sequences belong to another
class of transactivation sequences for which the struc-
tural basis of action remains unclear. The structure sug-
gests that two classes of transactivation sequences may
cooperate in mediating transcription activation. This
potential transactivation surface is likely to be different
in pathway-restricted SMAD proteins.
A model for phosphorylation-induced heterotrimeriza-
tion between Smad4 and pathway-restricted SMAD pro-
teins is proposed on the basis of structural inference and
previous biochemical results. Phosphorylation bridges
two types of SMAD proteins, each possessing a unique
transactivation surface, through tightening of the con-
served trimer interface. Thus, a conserved phosphoryla-
tion switch is used to generate signal diversity by
bridging heterologous SMAD complexes, which turn on
specific genes through recruiting distinct coactivators.
Materials and methods
Protein expression and purification
The coding region of S4AF, corresponding to residues 273–552 of
human Smad4/DPC4, was subcloned into the pGEX expression vector
(Pharmacia) using a polymerase chain reaction (PCR)-based approach.
The recombinant S4AF was overexpressed at room temperature in
Escherichia coli. The glutathione S-transferase (GST)-fused S4AF in the
cell extract was absorbed to glutathione–sepharose 4B beads and
released by thrombin digestion after extensive washing. S4AF was further
purified on a DEAE–sepharose fast-flow column using a NaCl gradient
from 10–300 mM. Purified fractions were concentrated to 40 mg/ml.
Protein crystallization
Crystals of S4AF were grown at room temperature using the hanging-
drop vapor diffusion method. Purified S4AF (40 mg/ml) was mixed with
an equal volume of reservoir solution containing 100 mM HEPES
pH 7.5, 10% PEG 4000 and 200 mM LiSO4. Small crystals appeared
within two days which were used to perform macroseeding under the
conditions of 100 mM HEPES pH 7.5, 8% PEG 4000 and 200 mM
LiSO4. Crystals suitable for diffraction experiments (0.2 mm in dimen-
sions) grew within one week.
X-ray data collection and processing
Diffraction data were collected from a single crystal at room tempera-
ture using an RAXIS IV image plate system mounted on a Rigaku rotat-
ing-anode generator running at 50 kV, 100 mA. The detector distance
was 150 mm, the oscillation angle 1°, and the exposure time 30 min.
The starting spindle angle and scan range for data collection was opti-
mized using the software STRATEGY [48]. The diffraction data were
processed and merged using the DENZO/SCALEPACK software
packages [49]. The data collection statistics are shown in Table 1.
Structure determination
The structure was solved by molecular replacement using the CNS
software package [50]. The Smad4 MH2 domain monomer was used
as the search model [35] to locate the three S4AF molecules in the
asymmetric unit of the space group I4(1)22 using rotation and transla-
tion functions of CNS. After rigid-body refinement, the R factor was
35.4%. The calculated map immediately revealed the presence of
additional density for the SAD region. Initial positional refinement and
model building was performed with strict noncrystallographic symme-
try (NCS) operator on, which lowered the Rfree factor to 29.0%. Sub-
sequent positional refinement and model building were performed
without the NCS operator, which brought the Rfree factor down to
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Figure 9
Proposed model of the heteromeric interaction between Smad4 and
pathway-restricted SMAD proteins. The phosphorylated C-terminal tail
sequence (in ball-and-stick format) of the pathway-restricted SMAD
protein adopts an extended conformation to reach the interface between
two Smad4 subunits. The three monomers are shown in different colors.
Pathway-restricted SMAD
Smad4
Smad4
Phosphorylated C-terminal tail
L3 loop
H1
Structure
27%. Inclusion of water molecules at this stage lowered the Rfree to
25%. Refinement and model building with the simulated annealing
omit maps protocol removed model bias at several regions. Sulfate
molecules were built in at the final stage, which brought the Rfree to
21.80%. Model building was performed using CHAIN [51]. The final
statistics of the refinement are shown in Table 1.
Accession numbers
The coordinates have been deposited in the Protein Data Bank with
accession code 1DD1.
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